In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.

In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.

In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.

Dr Reddy's Laboratories' co-chairman and MD, GV Prasad, talks about his conversations with late founder Dr Anji Reddy, the company’s ‘Horizon 2’ strategy, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession aspects and his new book.

Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.

In this week's podcast edition of Five Must-Know Things podcast: US Medicare price negotiations get soft landing; Medicare negotiations and patent cliff acceleration; Novo Nordisk steps into heart failure; PCSK9s and the convenience battle; and an investor’s view of Korean biotech potential.

Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.